Time to dissect the autoimmune etiology of cancer antibody immunotherapy

A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors

(2019) Patrick Arnaud-Coffin et al.   INTERNATIONAL JOURNAL OF CANCER

Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients

(2019) Marie-Léa Gauci et al.   MELANOMA RESEARCH

Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States

(2019) Spencer C. Wei et al.   IMMUNITY

A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors

(2019) Jeroen de Filette et al.   HORMONE AND METABOLIC RESEARCH

Immunogenic neoantigens derived from gene fusions stimulate T cell responses

(2019) Wei Yang et al.   NATURE MEDICINE

Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes Mellitus With Infliximab

(2019) Beckey Trinh et al.   DIABETES CARE

Immune checkpoint inhibitor‐induced Type 1 diabetes: a systematic review and meta‐analysis

(2019) H. K. Akturk et al.   DIABETIC MEDICINE

Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events

(2019) Yousef R. Badran et al.   Journal for ImmunoTherapy of Cancer

High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma

(2018) Alexander T. Faje et al.   CANCER

Immune Recognition of β-Cells: Neoepitopes as Key Players in the Loss of Tolerance

(2018) Eddie A. James et al.   DIABETES

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

(2018) Angeliki M. Stamatouli et al.   DIABETES

Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis

(2018) Yinghong Wang et al.   INFLAMMATORY BOWEL DISEASES

Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody

(2018) Michiru Shiba et al.   INTERNAL MEDICINE

Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

(2018) Giulia C. Leonardi et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

(2018) Syed S. Mahmood et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Adverse Events Associated with Immune Checkpoint Blockade

(2018)   NEW ENGLAND JOURNAL OF MEDICINE

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade

(2018) Kerry Reynolds et al.   ONCOLOGIST

Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients

(2018) Oded Sagiv et al.   OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY

Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis

(2018) Qiang Su et al.   Journal of Immunology Research

SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy

(2018) C E Higham et al.   Endocrine Connections

Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson

(2018) Yinghong Wang et al.   Journal for ImmunoTherapy of Cancer

PD-1 Inhibitor Immune-Related Adverse Events in Patients with Preexisting Endocrine Autoimmunity

(2018) Halis Kaan Akturk et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

(2018) Kathryn C. Arbour et al.   JOURNAL OF CLINICAL ONCOLOGY

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-α and-γ via IRF1 induction

(2018) Maikel L. Colli et al.   EBioMedicine

Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes

(2018) Jordan J. Wright et al.   DIABETES CARE

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis

(2018) Yinghong Wang et al.   NATURE MEDICINE

Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case–Control Study

(2018) Yael Eshet et al.   Cancer Immunology Research

The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy

(2018) Arabella Young et al.   Cancer Immunology Research

Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors

(2018) Emma C. de Moel et al.   Cancer Immunology Research

Clinical characterization of colitis arising from anti-PD-1 based therapy

(2018) Daniel Y Wang et al.   OncoImmunology

Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer

(2018) Yukihiro Toi et al.   JAMA Oncology

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study

(2018) Hamzah Abu-Sbeih et al.   Journal for ImmunoTherapy of Cancer

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

(2017) Paul M Ridker et al.   LANCET

Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma

(2017) Aikaterini Tsiogka et al.   MELANOMA RESEARCH

Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies

(2017) David J. Byun et al.   Nature Reviews Endocrinology

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

(2017) Enfu Hui et al.   SCIENCE

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

(2017) Diego Chowell et al.   SCIENCE

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma

(2017) Florie Bertrand et al.   Nature Communications

Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract

(2017) Michael Dougan   Frontiers in Immunology

Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment

(2017) Brittney N. Newby et al.   Frontiers in Endocrinology

Nivolumab induced myxedema crisis

(2017) Uqba Khan et al.   Journal for ImmunoTherapy of Cancer

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

(2017) I. Puzanov et al.   Journal for ImmunoTherapy of Cancer

Managing Adverse Events With Immune Checkpoint Agents

(2016) Ramona Dadu et al.   CANCER JOURNAL

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

(2016) Lars Hofmann et al.   EUROPEAN JOURNAL OF CANCER

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

(2016) Krista Dubin et al.   Nature Communications

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

(2016) P.-L. Chen et al.   Cancer Discovery

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy

(2016) T. M. Johanns et al.   Cancer Discovery

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

(2016) Douglas B. Johnson et al.   JAMA Oncology

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis

(2015) Hansje-Eva Teulings et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY

Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity

(2015) Alison M. Paterson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

(2015) Emanuela Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Early-onset Crohn’s disease and autoimmunity associated with a variant in CTLA-4

(2014) Sebastian Zeissig et al.   GUT

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations

(2014) Desirée Schubert et al.   NATURE MEDICINE

Autoimmunity by haploinsufficiency

(2014) F. Rieux-Laucat et al.   SCIENCE

Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4

(2014) H. S. Kuehn et al.   SCIENCE

Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody

(2014) S. Iwama et al.   Science Translational Medicine

In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

(2014) C. Wang et al.   Cancer Immunology Research

Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome

(2013) Dan Knights et al.   GUT

The B7-Independent Isoform of CTLA-4 Functions To Regulate Autoimmune Diabetes

(2013) M. Stumpf et al.   JOURNAL OF IMMUNOLOGY

Ipilimumab-induced autoimmune adrenalitis

(2013) Le Min et al.   Lancet Diabetes & Endocrinology

How Does Type 1 Diabetes Develop?: The Notion of Homicide or  -Cell Suicide Revisited

(2011) M. A. Atkinson et al.   DIABETES

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug-Induced Graves Disease From CTLA-4 Receptor Suppression

(2011) Gary Borodic et al.   OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY

Production of therapeutic antibodies with controlled fucosylation

(2010) Naoko Yamane-Ohnuki et al.   mAbs

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inflammatory Bowel Disease

(2009) Clara Abraham et al.   NEW ENGLAND JOURNAL OF MEDICINE